Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange

Stock News

02/13

Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1171533874"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171533874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171533874?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171533874","market":"hk","top_or_hot":-1,"title":"Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange","media":"Stock News","content":"<p>Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-13 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_HEX","symbol_name":"港交所","start_time":0,"source_url":"","article_id":"1171533874","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171533874","pubTimestamp":1770984975,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"药企Prolius Medicine向港交所提交上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"HEXmain":1,"09939":1},"content_text":"Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}